We are a bioincubator helping emerging biotechs decreasing their time to seed funding.

We have a growing commitment to engineering innovation that improves health industry efficiency.

latest news older news

Univercells granted $14.3 Million to deliver affordable measles and rubella vaccines using its NevoLine™ manufacturing platform

Univercells announces that it has been awarded a $14.3 million grant by the Bill & Melinda Gates Foundation to increase the availability of measles and rubella (M&R) vaccines in low- and middle-income countries (LMICs). Univercells will adapt the process design of its proprietary NevoLine™ platform to deliver affordable M&R vaccines.  Please discover the press release here.

Read more

Bone Therapeutics’ cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure

The leading biotech company focused on the development of innovative cell and biological therapeutics to address high unmet medical needs in orthopaedics and bone diseases, today announces that its allogeneic cell therapy product, ALLOB, successfully completed the 12 months follow-up period of a Phase IIa study in patients undergoing a lumbar spinal fusion procedure. Discover the press relaese here.

Read more
Learn more about our events all events next event


Comment préparer votre levée de fonds?

Les Associés Deloitte & Laga ont le plaisir de vous inviter à une série de séminaires consacrés à l’innovati...

Read more